Suele darse valor a una dieta en función de cuánto contribuye a proteger la salud. Pero en una nueva investigación se ha examinado la cuestión desde la perspectiva de cuánto gas con efecto invernadero acarrea seguir cada dieta, teniendo en cuenta el proceso que sig …
La mejor dieta para luchar contra el calentamiento global Read More »
En este Short veremos cómo es posible descubrir síntomas del Mal de Alzheimer a través de los ojos. …
En vez de construir en Marte desde cero un edificio que sirva de base habitable, aprovechar cavernas, así como de tubos de lava, sería una opción mucho mejor, para reducir el trabajo y el gasto de materiales de construcción, y en muchos casos para disponer de protecci&oac …
Planificando la exploración robótica de cuevas marcianas Read More »
Invitae (NYSE: NVTA), a leading medical genetics company, and Deerfield Management Company today announced a partnership to advance genetics-based drug discovery and development in rare disease.
Invitae and Deerfield Management Partner to Create Novel Therapeutics for Rare Diseases Read More »
BioBam, a leading bioinformatics software company, announces the renewal of its KEGG license through a Business Provider Agreement with Pathway Solutions Inc., the exclusive worldwide licensing agent for KEGG resources.
BioBam Renews KEGG Pathway Licensing for OmicsBox Read More »
Biohaven Ltd. (NYSE: BHVN) today announced that it acquired global rights, excluding China regions, for the development of an oral, brain-penetrant, dual inhibitor of Tyrosine Kinase 2 (TYK2) and Janus Kinase 1 (JAK1) for the treatment of brain disorders.
Capstan Therapeutics, Inc. today announced the appointment of Justin Thacker as Chief Financial Officer and Jeffrey Pepe, J.D., Ph.D. as General Counsel.
Alzamend Neuro, Inc. today announced the completion of the clinical portion of its Phase IIA multiple ascending dose (“ MAD ”) study for dementia related to Alzheimer’s.
Spectrum Pharmaceuticals, Inc. announced today financial results for the three-month period and full year ended December 31, 2022.
Flare Therapeutics Inc. announced a $123 million Series B financing co-led by GordonMD® Global Investments LP and Pfizer Ventures, with participation from existing investors Boxer Capital, Casdin Capital, Eventide Asset Management, Invus Financial Advisors, Nextech Invest and Third Rock Ventures and new investors Agent Capital, Eli Lilly and Company, Memorial Sloan Kettering Cancer Center, Novartis,
Flare Therapeutics Announces Oversubscribed $123 Million Series B Financing Read More »
